HER2- / Triple Negative C4161001

Study #C4161001

Phase 1/2A Dose Escalation, Finding and Expansion Study Evaluation Safety, Tolerability, Pharmacokinetics, Pharacodynamics and Anti Tumore Activity of PF-07104091 as a Single Agent and in Combination Therapy